VivoSeq
Other

Primary Aldosteronism

25

Pipeline Programs↗

12

Active Trials↗

9

Companies Involved↗

Primary Aldosteronism is an emerging landscape with 25 programs across 9 companies. The most active players are Damian Pharma AG, Viatris Specialty LLC, Novartis. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

25/100

Completion Rate

92/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Damian Pharma AG

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 3Bayer logo

Bayer

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

31

clinical trials

Completed12 · 39%
Recruiting9 · 29%
Unknown status6 · 19%
Not yet recruiting3 · 10%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

31 trials

Statin Combined with Amlodipine Treats Primary Aldosteronism
Recruiting·TThird Military Medical University·Phase 4·NCT06523465·180 enrolled
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
Recruiting·—·Phase 4·NCT05030545·40 enrolled
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
Recruiting·TThird Military Medical University·N/A·NCT07137364·350 enrolled
Unilateral Primary Aldosteronism, Mineralocorticoid Antagonists Versus Surgical Treatment
Recruiting·GGöteborg University·N/A·NCT05797558·80 enrolled
Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism
Recruiting·UUniversity of Calgary·Phase 2·NCT05472493·30 enrolled
Finerenone for Patients With Primary Aldosteronism (FAIRY)
Recruiting·—·Phase 4·NCT06457074·306 enrolled
Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate
Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06616142·12 enrolled
Study on the Application of Liquid Chromatography-Tandem Mass Spectrometry for the Determination of Aldosterone and Renin Activity in the Diagnosis of Primary Aldosteronism by Captopril Test
Recruiting·PPeking Union Medical College Hospital·N/A·NCT07691801·800 enrolled
Efficacy and Safety of Finerenone Compared to Spironolactone in Treatment of Primary Aldosteronism
Recruiting·BBangladesh Medical University·Preclinical·NCT07688928·104 enrolled
Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT05814770·96 enrolled
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07470983·60 enrolled
Intensive Versus Standard Blood Pressure Control in Patients With Primary Aldosteronism (Intensia-Aldo): A Multi-center, Randomized Controlled Trial
Not yet recruiting·CChongqing Medical University·Preclinical·NCT07673445·3,830 enrolled
A Study of CIN-107 in Adults With Primary Aldosteronism
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT04605549·15 enrolled
Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
Completed·—·Phase 4·NCT05924620·60 enrolled
Calcium Channel Blockade in Primary Aldosteronism
Completed·—·Phase 2·NCT04179019·15 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)